FENNEC PHARMACEUTICALS INC

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

FENC$10.83+10.4%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations


· · Year Ended
· · December 31, · · December 31,
	2023		2022

Revenue
PEDMARK(R) product sales, net		$21,252		$1,535
Cost of products sold		(1,259)		(86)
Gross profit		19,993		1,449

Operating expenses:
Research and development		56		3,531
Selling and marketing		12,123		2,785
General and administrative		20,585		17,722

Total operating expenses		32,764		24,038
Loss from operations		(12,771)		(22,589)

Other (expense)/income
Unrealized foreign exchange gain/(loss)		5		(9)
Amortization expense		(287)		(149)
Unrealized loss on securities		(39)		(184)
Interest income		441		195
Interest expense		(3,394)		(978)
Total other (expense)/income		(3,274)		(1,125)

Net loss		$(16,045)		$(23,714)

Basic net loss per common share		$(0.60)		$(0.90)
Diluted net loss per common share		$(0.60)		$(0.90)
Weighted-average number of common shares outstanding basic		26,574		26,275
Weighted-average number of common shares outstanding diluted		26,574		26,275

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.